AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25565364
Drug: Watchful waiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watchful waiting with protocol-defined initiation of tamsulosin therapy if symptoms did not improve (WW-All)
Trial: 21775681
Drug: Rituximab (anti-CD20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (anti-CD20 monoclonal antibody), administered as four weekly doses.
Trial: 11433853
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean dose, 8.6 mg)
Trial: 11433853
Drug: Midazolam plus
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam plus additional midazolam as needed (mean total dose, 12.2 mg)
Trial: 11433853
Drug: Fentanyl (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.4 micrograms/kg) plus midazolam (mean dose, 5.7 mg)
Trial: 11433853
Drug: Fentanyl (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.4 micrograms/kg), midazolam (mean dose, 5.8 mg) and methohexital as needed (mean dose, 61.0 mg)
Trial: 9425919
Drug: Percutaneous acetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous acetic acid injection (50% acetic acid)
Trial: 9425919
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (absolute ethanol)
Trial: 31904855
Drug: IVIG (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (0.4 g/kg/d) for five consecutive days
Trial: 24739906
Drug: Combination mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination mouth rinse (0.03% triclosan, 0.05% sodium fluoride, and 5% xylitol)
Trial: 15359583
Drug: 2, 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2, 5, 10, or 25 mg tadalafil
Trial: 11938824
Drug: Defibrase injection
DrugBank: Batroxobin (DB09005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrase injection (DI)
Trial: 11938824
Drug: Acanthopanax injection
RxNorm normalized name: Manyprickle Acanthopanax
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acanthopanax injection (AI)
Trial: 11938824
Drug: Ginaton injection
RxNorm normalized name: Genaton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginaton injection (GI)
Trial: 1389316
Drug: Immunoglobulin (Endobulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (Endobulin, Immuno) administered intravenously at a dose of 100 mg/kg/week during the first 3 months, followed by 2 x 200 mg/kg/month during the 4th, 5th, and 6th months
Trial: 1389316
Drug: No immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immunoglobulin administered
Trial: 30732583
Drug: Comprehensive interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive interventions focused on treatment intensification and adherence improvement.
Trial: 27443526
Drug: Extra Virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra Virgin Olive Oil (EVOO), 50 ml daily for 3 weeks
Trial: 27443526
Drug: Refined Olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined Olive Oil (ROO), 50 ml daily for 3 weeks
Trial: 27002934
Drug: Intravenous rucaparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rucaparib (intermittent dosing schedule)
Trial: 27002934
Drug: Oral rucaparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rucaparib (across all six dose levels)
Trial: 22868016
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg (maximum of 8 mg)
Trial: 14961167
Drug: MDK-group (supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDK-group (supplement with minerals and vitamin D plus vitamin K1)
Trial: 14961167
Drug: MD-group (supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-group (supplement with minerals and vitamin D)
Trial: 9627208
Drug: Anticonvulsant monotherapy
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant monotherapy (200mg CBZ, 500mg VPA, 100mg PHT)
Trial: 6614422
Drug: Buprenorphine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (both doses)
Trial: 3115662
Drug: Inhaled carbon
RxNorm normalized name: carbon dioxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled carbon dioxide (CO2) at constant flow into a breathing circuit
Trial: 3115662
Drug: Inhaled carbon
RxNorm normalized name: carbon dioxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled carbon dioxide (CO2) during exercise
Trial: 27225736
Drug: Balneotherapy (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy (21 sessions of spa treatment with 34.8 °C thermomineral water, 5 days a week)
Trial: 24152852
Drug: K‐712 (phytonutrient),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K‐712 (phytonutrient), 1 tab twice a day for one week/month
Trial: 24152852
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg orally once a week
Trial: 17187094
Drug: Bone tissue
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone tissue preserved in 98% glycerol solution at room temperature
Trial: 17187094
Drug: Microbiological analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiological analysis of 98% glycerol solution and bone fragments
Trial: 11865133
Drug: Entacapone treatment
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone treatment for 2 months
Trial: 2194280
Drug: Captopril treatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril treatment for 9 days in 15 patients with diabetic nephropathy
Trial: 2194280
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment for 8 weeks in 40 patients with diabetic nephropathy
Trial: 2194280
Drug: Metoprolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol treatment for 8 weeks in 40 patients with diabetic nephropathy
Trial: 2194280
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with captopril in patients with diabetic nephropathy
Trial: 2194280
Drug: Furosemide treatment
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide treatment adjusted for blood-pressure control in both groups
Trial: 318049
Drug: Periocular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injection of penicillin combined with multiple preoperative applications of topical chloramphenicol‐sulphadimidine
Trial: 318049
Drug: Topical chloramphenicol‐sulphadimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical chloramphenicol‐sulphadimidine
Trial: 23998556
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment regime
Trial: 24442560
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg once daily
Trial: 30668332
Drug: Wu chu
RxNorm normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wu chu yu tang (WCYT) 3.0 g three times per day for 4 weeks
Trial: 30668332
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once per day and WCYT placebo (3.0 g) three times per day for 4 weeks
Trial: 23245537
Drug: Sertraline or
RxNorm normalized name: sertraline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline or Bupropion for 8 weeks
Trial: 20812339
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (no treatment)
Trial: 19460102
Drug: L-NAME (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (180 microg kg(−1)h(−1))
Trial: 17310385
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg/day)
Trial: 2878034
Drug: Intra-operative parenteral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative parenteral gentamicin and vancomycin (with streptomycin in the irrigating solution)
Trial: 30845949
Drug: Health Integrator
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Integrator with monthly health coaching sessions
Trial: 25803348
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids combined with antibiotics
Trial: 25803348
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids as monotherapy
Trial: 22139679
Drug: Celecoxib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (selective COX-2 inhibitor)
Trial: 8126257
Drug: Ibuprofen 2400
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 2400 mg/day
Trial: 1556674
Drug: Ibuprofen (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (both doses)
Trial: 3432173
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride (90 mg/day)
Trial: 28990651
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIT) - three exercise sessions per week for 4 weeks, with weekly maintenance sessions if surgery was delayed.
Trial: 27267105
Drug: Pomalidomide plus
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide plus low-dose dexamethasone (POM + LoDEX)
Trial: 23316791
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment plus whole body vibration (WBV) during supervised physical therapy
Trial: 23316791
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment (control group)
Trial: 23316791
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment plus WBV
Trial: 21644804
Drug: Conjoint treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjoint treatment
Trial: 21644804
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of treatment modality
Trial: 15787815
Drug: Spironolactone 200
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 200 mg daily
Trial: 1606994
Drug: Digoxin 0.5
RxNorm normalized name: digoxin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.5 to 1 mg.d‐1 p.o. for 6 days
Trial: 31560372
Drug: Oral Lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Lefamulin (600 mg every 12 hours for 5 days)
Trial: 31560372
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg every 24 hours for 7 days)
Trial: 31560372
Drug: Oral Lefamulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Lefamulin
Trial: 21537360
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment (ICBT)
Trial: 12520749
Drug: NP regimen
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP regimen (vinorelbine + cisplatin); vinorelbine: 25 mg/m2 on days 1 and 8, cisplatin: 35 mg/m2 on days 1-3
Trial: 12520749
Drug: MVP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVP regimen (mitomycin + vindesine + cisplatin); mitomycin: 6 mg/m2 on day 1, vindesine: 3 mg/m2 on days 1 and 8, cisplatin: 30 mg/m2 on days 1-3
Trial: 7897422
Drug: 240 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/day ginkgolide B
Trial: 7897422
Drug: 360 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg/day ginkgolide B
Trial: 26446653
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid only (Control)
Trial: 22869103
Drug: Acyclovir (twice-daily)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (twice-daily)
Trial: 19838489
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (Camellia sinensis) 250 mg capsules
Trial: 17309331
Drug: G17DT in
RxNorm normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G17DT in combination with gemcitabine
Trial: 18509176
Drug: Docetaxel therapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel therapy
Trial: 11340898
Drug: Three-drug regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimens including docetaxel
Trial: 10036460
Drug: Nursing practice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing practice model based on Aristotelian theory and Rogers' science; specific dosage and duration not mentioned.
Trial: 30018942
Drug: Pulsed therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed therapeutic ultrasound (PUS) administered 2 times weekly for 6 weeks
Trial: 30018942
Drug: Kneading massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kneading massage (KM) administered 2 times weekly for 6 weeks
Trial: 18426851
Drug: Intratracheal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours
Trial: 18426851
Drug: Surfactant only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant only (100 mg/kg of survanta), every 8 hours
Trial: 16490736
Drug: Surgery +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery + chemotherapy (cisplatin 80 mg/m² on Day 1 and 5-fluorouracil 500 mg/m²/day on Days 1-5)
Trial: 9350066
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pamidronate
Trial: 9350066
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pamidronate
Trial: 2722900
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg twice daily for 3 days
Trial: 30351511
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone 1250 mg/day for 3 days
Trial: 30351511
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone 625 mg/day for 3 days
Trial: 28598202
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of amlodipine administered in the evening
Trial: 28598202
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of amlodipine administered in the morning
Trial: 21609410
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (5 mg daily)
Trial: 16871477
Drug: Tizanidine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (0.05 mg/kg/day)
Trial: 15027185
Drug: BCG-PSN local
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-PSN local injection following CO2 laser resection
Trial: 15027185
Drug: Interferon subcutaneous
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon subcutaneous injection following CO2 laser resection
Trial: 11576768
Drug: Rifampicin (RIF)
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin (RIF) 450 mg capsule
Trial: 11576768
Drug: Rifampicin‐isoniazid (RIF‐INH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin‐isoniazid (RIF‐INH) 450+300 mg FDC capsule
Trial: 2030925
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of enteric coated (EC) pancreatic enzymes (patient's usual dose)
Trial: 2030925
Drug: Small doses
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small doses of enteric coated (EC) pancreatic enzymes (1/4 usual dose)
Trial: 7093115
Drug: Single morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single morning dose of methyldopa
Trial: 7093115
Drug: Single evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single evening dose of methyldopa
Trial: 10449266
Drug: Intravaginal 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 5-fluorouracil (5-FU) cream
Trial: 10449266
Drug: Intravaginal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal placebo cream
Trial: 2468964
Drug: N-acetylcysteine (NAC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC, 2,400 mg X 2) + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Trial: 2468964
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Trial: 31794478
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment (control)
Trial: 29040598
Drug: Metformin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (up to 1 g twice a day)
Trial: 23173821
Drug: Adalimumab (160/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter)
Trial: 23173821
Drug: Adalimumab (160/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter) in patients using corticosteroids at baseline (N=90)
Trial: 11505349
Drug: 17beta-estradiol, 2mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol, 2mg, given orally twice in 14 hours before the operation
Trial: 9305559
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion at 6.0 +/- 0.4 micrograms.kg-1.min-1 in young adults
Trial: 9305559
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion at 4.3 +/- 0.3 micrograms.kg-1.min-1 in elderly patients
Trial: 9305559
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion in patients with low plasma cholinesterase activity
Trial: 9305559
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion titrated to maintain 95 +/- 4% twitch depression
Trial: 9305559
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion with or without antagonism
Trial: 8280653
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MAP) 1g/day i.m. 5 days/week for 4 weeks and then 500 mg twice a week
Trial: 8280653
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/day orally
Trial: 27103382
Drug: Anticoagulant users
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant users (n=32)
Trial: 27103382
Drug: Baseline anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline anticoagulant use
Trial: 27103382
Drug: Anticoagulant use
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant use at any time during the study
Trial: 26138109
Drug: Dorsal onlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal onlay buccal mucosal graft urethroplasty
Trial: 23931150
Drug: Dorsal inlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal inlay buccal mucosal graft urethroplasty
Trial: 17351767
Drug: GABAB receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABAB receptor agonist baclofen